Inhibikase wins FDA orphan drug designation for IKT-001 in PAH - IKT News | RalliesInhibikase wins FDA orphan drug designation for IKT-001 in PAH
I
IKT• FDA grants orphan drug designation for IKT-001
- Inhibikase Therapeutics received FDA orphan drug designation for IKT-001 to treat pulmonary arterial hypertension.
- IKT-001 is a prodrug of imatinib; designation targets an estimated 50,000 U.S. patients with PAH.
- Status may support development incentives, including potential tax credits, fee waivers, and seven years of exclusivity upon approval.
